Related Experiment Video
Updated: May 26, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Pentraxins and Alzheimer's disease: at the interface between biomarkers and pharmacological targets
Cecilia Osera1, Alessia Pascale, Marialaura Amadio
1Department of Drug Sciences, Section of Pharmacology, Laboratory of Neurobiology and Neuropharmacology of Neurodegenerative Diseases and the Nervous System, University of Pavia, Italy. cecilia.osera@unipv.it
Abstract:
Alzheimer's disease (AD) is a neurodegenerative disorder involving deposition of misfolded proteins in vulnerable brain regions leading to inexorable and progressive neuronal loss and deterioration of cognitive functions. The AD brain displays features typical of chronic inflammation as defined by the presence of activated microglia and by an excessive amount of neuroinflammatory components such as cytokines and acute-phase proteins. This review aims to shed light on the role of the immune processes involved in AD, focusing on a family of inflammatory modulators belonging to the acute-phase proteins and crucial components of the humoral arm of innate immunity: pentraxins. In particular we analyze function of the pentraxins in AD, their upregulation in the brain and their contribution to neurodegeneration. Additionally, we highlight the role of pentraxins as putative AD biomarkers and as pharmacological therapeutic targets.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Pharmacodynamics in Geriatric Patients: Effects of Age
Alzheimer Disease l: Introduction
Ligand-Gated Ion Channel Receptor: Gating Mechanism